MoneyWorks4Me

Ajanta gets listed in Forbes Asia's '200 Best under Billion' 2014

19 Aug 2014 Evaluate

Ajanta Pharma, a specialty focused pharmaceutical formulation company, has been listed on Forbes Asia's 'Best Under a Billion' 2014 list. This is the third consecutive listing of the company since 2012.

The ‘Best Under  A Billion’ list is published by Forbes Asia to recognize 200 small and midsized publicly listed companies in Asia Pacific region with annual revenue under $1 billion. The companies were selected based on three stringent categories of profitability, growth, and modest indebtedness from a universe of 17,000 stock-traded companies across Asia-Pacific region.

Ajanta Pharma is engaged in manufacturing pharmaceutical products. The company runs three divisions -- prescription drugs, OTC and institutional sales.

Ajanta Pharma Share Price

3560.55 19.85 (0.56%)
28-Aug-2026 09:55 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1914.25
Dr. Reddys Labs. 1181.25
Cipla 1416.15
Lupin 2161.00
Zydus Lifesciences 1181.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: